Semaglutide and Domperidone Drug Interaction
Semaglutide delays gastric emptying, which can theoretically affect the absorption of concomitantly administered oral medications. [1]
No specific, clinically established pharmacokinetic drug–drug interaction between semaglutide and domperidone has been identified in product-label drug-interaction data. [1]
Mechanism of Semaglutide–Mediated Absorption Effects
Semaglutide delays gastric emptying and therefore has the potential to impact absorption of concomitantly administered oral medications. [1]
In semaglutide clinical pharmacology trials at a 1 mg steady-state exposure, semaglutide did not affect the absorption of orally administered medications assessed in those studies. [1]
Pharmacodynamic Evidence for Prokinetic Co-administration
A physiologic study in nine healthy male volunteers evaluated GLP-1–mediated effects on gastric physiology with co-administration of prokinetic drugs including domperidone. [2]
That study design supports the concept of potential pharmacodynamic interaction at the level of gastric motility when a GLP-1 effect on gastric emptying is opposed by a prokinetic agent. [2]
Clinical Interaction Summary for Domperidone
Semaglutide use may change the rate and extent of absorption of oral medications because of delayed gastric emptying, so monitoring for altered effect of orally administered drugs is recommended in semaglutide labeling. [1]
Domperidone is a prokinetic agent used for gastrointestinal indications, so its primary relevance with semaglutide is modulation of gastric motility rather than a documented direct pharmacokinetic interaction. [2]
Cardiac Safety Considerations With Domperidone
Domperidone has been associated with serious cardiac adverse events, including QT prolongation, torsade de pointes, cardiac arrest, and sudden death. [3]
QT-prolongation risk assessment for domperidone should therefore be performed when domperidone is prescribed, independent of semaglutide’s gastric motility effect. [3]
Medication-Management Implications
Concomitant oral medications should be monitored for clinical effect changes when semaglutide is used. [1]
No semaglutide label-specific guidance exists for domperidone timing adjustment beyond this general oral-medication monitoring recommendation. [1]
Practical Safety Monitoring
Monitoring for reduced or delayed therapeutic effects of oral drugs is appropriate during semaglutide therapy due to its gastric-emptying effect. [1]
Monitoring for domperidone-related cardiac risk factors and adverse effects is appropriate because domperidone carries a known QT-related serious risk profile. [3]